THANK YOU FOR SUBSCRIBING
The presentation explores the potential advantages of leveraging patient-centric approaches in drug development.
FREMONT, CA: Altavant Sciences, a clinical-stage biopharmaceutical company, specializing in the development of patient-centric drugs for respiratory conditions, recently conducted a poster presentation describing its unique drug development process at the Pulmonary Hypertension Association’s Annual PH Professional Network (PHPN) Symposium in Washington, D.C.
The protocol development for the ELEVATE 1 proof-of-concept clinical trial for rodatristat ethyl, Altavant’s lead candidate for pulmonary arterial hypertension (PAH), revolved around the principle of patient centricity. The company empowers patients to make informed decisions during participation in the study, providing compelling and relatable educational content.
Altavant partnered with Greater Gift, a nonprofit organization donating vaccines to people in need in honor of each of the ELEVATE clinical trial participants. It aims to expand its patient-centric framework by exploring various opportunities to engage individuals with PAH through social media channels, advisory boards, and advocacy organizations, enabling the engagement to enhance and advance its clinical development work.
The involvement of patients in the clinical trial design and implementation process is vital for the development of new medicines. According to the published literature, the trials designed with patient input deliver faster enrollment, potentially reducing the development costs. Besides, the patient feedback is more positive and leads to higher retention when compared to industry standards. The company aims to expand its patient-centric practices across development practices and evaluate their impact.
The candidate drug rodatristat ethyl is a tryptophan hydroxylase (TPH) inhibitor designed to reduce the peripheral production of serotonin in the body. According to a significant portion of scientific evidence, the dysregulated peripheral serotonin production potentially acts as a trigger of aberrant proliferation and constriction of the smooth muscle cells in the wall of the pulmonary arteries, causing them to restrict blood flow in PAH.
The drug, rodatristat ethyl, can potentially stop or reverse the pathology of diseases such as PAH, idiopathic pulmonary fibrosis (IPF), and sarcoidosis, driven by excessive serotonin production by reducing the circulating serotonin levels. The company is currently testing the mechanism of action in the ELEVATE 1 proof-of-concept Phase 2a study of rodatristat ethyl in patients with PAH.